Core Laboratories
CLB
162 hedge funds and large institutions have $920M invested in Core Laboratories in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 57 increasing their positions, 55 reducing their positions, and 20 closing their positions.
50% more capital invested
Capital invested by funds: $615M → $920M (+$305M)
22% more call options, than puts
Call options by funds: $638K | Put options by funds: $524K
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
4% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 55
0.78% more ownership
Funds ownership: 98.34% → 99.12% (+0.78%)
0% more funds holding
Funds holding: 162 → 162 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$14.3M |
| 2 |
BlackRock
New York
|
+$5.4M |
| 3 |
EARNEST Partners
Atlanta,
Georgia
|
+$5.02M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$4.33M |
| 5 |
GJL
Gendell Jeffrey L
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DLA
Douglas Lane & Associates
New York
|
-$6.98M |
| 2 |
VanEck Associates
New York
|
-$4.69M |
| 3 |
FAM
Fred Alger Management
New York
|
-$4.56M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$1.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MOACM
176
Mutual of America Capital Management
New York
| – | -$124K | -9,217 | Closed |
|
|
TRCT
177
Tower Research Capital (TRC)
New York
| – | -$47K | -3,452 | Closed |
|
|
HDIM
178
Hanson & Doremus Investment Management
Burlington,
Vermont
| – | -$15K | -1,148 | Closed |
|
|
MAM
179
Meeder Asset Management
Dublin,
Ohio
| – | -$12K | -854 | Closed |
|
|
CYG
180
Clean Yield Group
Norwich,
Vermont
| – | -$4K | -262 | Closed |
|
181
Optiver Holding
Amsterdam,
Netherlands
| – | -$4K | -253 | Closed |
|
CLB Hedge Fund Activity: Q4 2022 in Review
162 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Core Laboratories (CLB) for Q4 2022, worth a combined $920M — up 50% from $615M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CLB positions and 20 closed out — a net gain of 4 holders — while 57 added to existing stakes and 55 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $14.3M. The largest seller was Douglas Lane & Associates, cutting an estimated $6.98M.
- 162 institutional investors held Core Laboratories (CLB) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $920M of Core Laboratories stock for Q4 2022, up 50% quarter-over-quarter.
- 24 funds opened new Core Laboratories positions in Q4 2022 and 20 closed out, a net change of +4 holders.
- The largest Core Laboratories buyer in Q4 2022 was Royce & Associates, an estimated $14.3M added.
- The largest Core Laboratories seller in Q4 2022 was Douglas Lane & Associates, an estimated $6.98M sold.
Based on aggregated 13F filings for Q4 2022.